Endometrial cancer: open trials in South Korea

• NCT05646316

  Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

  Trial Treatment · Phase 3 · NRG Oncology

  Gachon University Gil Hospital, Incheon · Samsung Changwon Hospital, Seoul · Ewha Woman's University Mokdong Hospital, Seoul · Gangnam Severance Hospital, Seoul · Asan Medical Center, Seoul

  Registry updated 2026-11-06

• NCT06586957

  A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  Trial Treatment · Phase 1 · NiKang Therapeutics, Inc.

  Chung-Ang University Gwangmyeong Hospital, Gwangmyeong · Yonsei Cancer Center / Severance Hospital, Seoul

  Registry updated 2026-11-05

• NCT05579366

  Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  Trial Treatment · Phase 1/2 · Genmab

  Korea Institute of Radiological and Medical Sciences, Seoul

  Registry updated 2026-11-04

• NCT06400472

  A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  Trial Treatment · Phase 1 · Eli Lilly and Company

  National Cancer Center, Goyang-si Gyeonggi-do

  Registry updated 2026-11-04

• NCT06695845

  A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  Trial Treatment · Phase 2 · Jazz Pharmaceuticals

  Samsung Medical Center, Gangnam-Gu · Korea University Guro Hospital, Guro-gu · Chonnam National University Hwasun Hospital, Hwasun-Eup · Seoul National University Hospital, Jongno-gu · Severance Hospital, Seodaemun-gu · Asan Medical Center, Seoul · The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul · Seoul National University Bundang Hospital, Seoul · The Catholic University of Korea St. Vincent's Hospital, Suwon · National Cancer Center Suwon, Suwon

  Registry updated 2026-11-04

• NCT06760819

  A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  Trial Treatment · Phase 2 · Bayer

  Seoul National University Hospital | Oncology, Jongno -Gu · Asan Medical Center - Oncology, Seoul · Severance Hospital | Oncology, Seoul · Samsung Medical Center | Oncology, Seoul

  Registry updated 2026-11-04

• NCT07286331

  A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

  Trial Treatment · Phase 3 · GlaxoSmithKline

  Cheongju Chungcheongbuk-do · Daegu · Seongnam-si Gyeonggi-do · Seoul

  Registry updated 2026-11-03

• NCT07684599

  A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)

  Trial Treatment · Phase 3 · GlaxoSmithKline

  Daegu

  Registry updated 2026-11-03

• NCT07262619

  EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

  Trial Treatment · Phase 1/2 · Eikon Therapeutics

  Inje University Haeundae Paik Hospital, Busan · Korea University Anam Hospital, Seoul · Ajou University School of Medicine & Graduate School of Medicine, Suwon

  Registry updated 2026-10-30

• NCT07022483

  A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

  Trial Treatment · Phase 3 · Daiichi Sankyo

  Keimyung University Dongsan Hospital, Daegu · Samsung Medical Center, Seoul · Seoul National University Hospital, Seoul

  Registry updated 2026-10-27

• NCT06172478

  A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  Trial Treatment · Phase 2 · Daiichi Sankyo

  Kyungpook National University Chilgok Hospital, Daegu · National Cancer Center, Gyeonggi-do · Seoul National University Bundang Hospital, Seongnam · CHA Bundang Medical Center, CHA University, Seongnam · Seoul National University Hospital, Seoul · Severance Hospital, Yonsei University Health System, Seoul · Samsung Medical Center, Seoul · Asan Medical Center, Seoul

  Registry updated 2026-10-26

• NCT06340568

  A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  Trial Treatment · Phase 3 · BioNTech SE

  Samsung Changwon Hospital, Changwon · Keimyung Univty Dongsan Hospital, Daegu · National Cancer Center, Goyang · Seoul National University Bundang Hospital, Seongnam · CHA Bundang Medical Center, Seongnam-si · Seoul National University Hospital, Seoul · Asan Medical Center, Seoul · Korea University Anam Hospital, Seoul · Samsung Medical Center, Seoul · Ewha Womans University Seoul Hospital, Seoul · Gangnam Severance Hospital, Yonsei University Health System, Seoul · The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul · Severance Hospital, Yonsei University Health System, Seoul

  Registry updated 2026-10-16

• NCT05123482

  A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

  Trial Treatment · Phase 1/2 · AstraZeneca

  Seoul

  Registry updated 2026-10-13

• NCT06952504

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Keimyung University Dongsan Hospital (Site 3105), Daegu · National Cancer Center (Site 3106), Gyeonggi-do · Severance Hospital, Yonsei University Health System (Site 3101), Seoul · Samsung Medical Center (Site 3104), Seoul · Seoul National University Hospital (Site 3102), Seoul · Asan Medical Center (Site 3103), Seoul

  Registry updated 2026-10-13

• NCT06989112

  DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  Trial Treatment · Phase 3 · AstraZeneca

  Goyang-si · Seoul · Suwon

  Registry updated 2026-10-13

• NCT06977594

  Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer

  Trial Treatment · Seoul National University Hospital

  Seoul National University Hospital, Seoul

  Registry updated 2026-10-07

• NCT05417594

  Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

  Trial Treatment · Phase 1/2 · AstraZeneca

  Seoul

  Registry updated 2026-10-05

• NCT05797168

  Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

  Trial Treatment · Phase 1/2 · AstraZeneca

  Seoul

  Registry updated 2026-10-05

• NCT04585750

  The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  Trial Treatment · Phase 1/2 · PMV Pharmaceuticals, Inc

  Asan Medical Center, Seoul · Severance Hospital Yonsei University, Seoul · Seoul University Hospital, Seoul · National Cancer Center, Seoul · Samsung Medical Center, Seoul

  Registry updated 2026-10-02

• NCT03564340

  Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

  Trial Treatment · Phase 1/2 · Regeneron Pharmaceuticals

  Yonsei University Health System, Seoul · Korea University Guro Hospital, Seoul · Samsung Medical Center, Seoul · Seoul National University Hospital, Seoul · Asan Medical Center, Univ. of Ulsan, Seoul

  Registry updated 2026-09-25

• NCT05489211

  Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  Trial Treatment · Phase 2 · AstraZeneca

  Seoul

  Registry updated 2026-09-23

• NCT06995833

  Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance

  Research · AstraZeneca

  Seoul

  Registry updated 2026-09-02

• NCT05150691

  A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

  Trial Treatment · Phase 1/2 · DualityBio Inc.

  National Cancer Center, Gyeonggi-do · Seoul National University Bundang Hospital, Gyeonggi-do · Severance hospital, Seoul · Samsung Medical Center, Seoul · Asan Medical Center, Seoul

  Registry updated 2026-08-27

• NCT04104776

  A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

  Trial Treatment · Phase 1/2 · Novartis Pharmaceuticals

  Keimyung University - Dongsan Medical Center, Daegu · National Cancer Center, Goyang-si · Gachon University Gil Medical Center, Incheon · Seoul National University Hospital, Seoul · Asan Medical Center, Seoul · The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul · Gangnam Severance Hospital, Seoul · Severance Hospital, Yonsei University Health System, Seoul

  Registry updated 2026-08-19

• NCT07044336

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  Trial Treatment · Phase 3 · AstraZeneca

  Goyang-si · Gwangjin-gu · Seoul · Songpa-gu · Suwon

  Registry updated 2026-07-29

All Endometrial cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error